Back to search

France· FR:65104826

NOXIBEN 2 mg, comprimé pelliculé

A eszopiclone product containing eszopiclone, registered in France by G.L. PHARMA (AUTRICHE), on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC N05CF04

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedNOXIBEN 2 mg, comprimé pelliculéATCN05CF04REGISTER NO.FR:65104826PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Eszopiclone is registered in 10 of 19 countries.

Countries holding a registration under ATC N05CF04 (eszopiclone), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 6 of them publish a price we can compare per daily dose

Eszopiclone · ATC N05CF04

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Finlandprice
  • Franceprice
  • Germany
  • Japan
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of eszopiclone costs, country by country.

Normalised to the WHO defined daily dose (2 mg), so markets compare like for like.

  • France: $0.13 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Eszopiclone · price per daily dose (2 mg)

USD · FX 28 Sept 2026

  • FR France$0.13
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
ESZOPICLONE
Manufacturer
G.L. PHARMA (AUTRICHE)
Country
France (FR)
ATC code
N05CF04
ATC class
Eszopiclone
Defined daily dose
2 mg, O
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930231234
    plaquette(s) PVC PVDC PVC-Aluminium de 14 comprimé(s)
    EUR 1.61

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

126 interactions on record for eszopiclone.

Graded by severity as the source publishes them — 13 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Eszopiclone · interactions on record

126 records

  • 13 severe
  • 113 moderate

Most severe, free to view

  • KetoconazoleH02CA03severe
  • ClarithromycinJ01FA09severe
  • KetoconazoleJ02AB02severe
  • Darunavir and cobicistatJ05AR14severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Eszopiclone in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All eszopiclone products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

  • Austria · Esogno
  • Bulgaria · Есогно
  • Czechia · Esogno
  • Germany · Esogno, Lunivia
  • Estonia · Esogno
  • Hungary · Esogno
  • Italy · Esnoxiben
  • Lithuania · Esogno
  • Latvia · Esogno
  • Poland · Esogno
  • Slovakia · Esogno

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d0ec43e7-9b1f-48de-8b4b-4904a6821e60
GET /v1/drugs/d0ec43e7-9b1f-48de-8b4b-4904a6821e60?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "65104826",
  "date_amm": "2020-03-09",
  "type_amm": "Procédure décentralisée",
  "numero_ue": null,
  "substance": "ESZOPICLONE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": "Warning disponibilité",
  "forme_pharmaceutique": "comprimé pelliculé",
  "voies_administration": "orale",
  "etat_commercialisation": "Non commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about eszopiclone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.